Results 21 to 30 of about 129 (105)

THE ROLE OF MODERN ANTIPLATELET THERAPY IN PREVENTION OF ATHEROTHROMBOSIS: THE IMPORTANCE OF CLOPIDOGREL AND ITS GENERIC DRUGS

Рациональная фармакотерапия в кардиологии, 2016
Current issues of atherothrombosis prevention and treatment optimization with antiplatelet therapy in patients with cardioascular diseases are discussed.
O. V. Gaisenok
doaj   +1 more source

THERAPEUTIC EQUIVALENCE OF ORIGINAL CLOPIDOGREL (PLAVIX) AND ITS GENERIC (EGITROMB). RESULTS OF COMPARATIVE RANDOMIZED CROSS-OVER BLIND STUDY

Рациональная фармакотерапия в кардиологии, 2016
Aim. To study therapeutic equivalence (efficacy, safety and tolerability) of original clopidogrel (Plavix) and its generic (Egitromb) in patients of high cardiovascular risk. Material and methods.
V. V. Yakusevich, A. S. Petrochenko, V. A. Simonov, N. Yu. Levshin, A. D. Deev   +4 more
doaj   +1 more source

Patient-specific choice of an antiplatelet drug for long-term therapy of coronary heart disease: rationale and implementationL

Медицинский совет, 2014
In all urbanized countries, more than half of overall mortality is conditioned by diseases caused by atherothrombosis in the arteries of heart and brain.
NA Mazur
doaj   +1 more source

Role of clopidogrel role in secondary prevention of ischemic stroke

Медицинский совет, 2014
The article tells discusses the role of antiplatelet therapy in the prevention of atherothrombotic stroke. There is data from large randomized studies which compared the effects of clopidogrel and acetylsalicylic acid drugs in reducing the risk of stroke.
K. S. Meshkova, V. V. Gudkova
doaj   +1 more source

POSSIBILITIES OF CLINICAL LABORATORY EVALUATION OF ANTIPLATELET THERAPY EFFECTIVENESS IN PATIENTS WITH ISCHEMIC HEART DISEASE

Рациональная фармакотерапия в кардиологии, 2015
Aim. To evaluate the functional activity of platelets by the optical standard aggregatometry and induced flow cytofluorometry during antiplatelet therapy with clopidogrel and acetylsalicylic acid (ASA).Material and methods.
O. V. Sirotkina, A. B. Laskovets, A. S. Lipunova, L. B. Gaykovaya, S. A. Boldueva, T. V. Vavilova   +5 more
doaj   +1 more source

UP TO DATE ANTIPLATELET THERAPY IN PATIENTS WITH HIGH RISK OF THROMBOTIC EVENTS AND REAL CLINICAL PRACTICE

Рациональная фармакотерапия в кардиологии, 2015
Aim. To assess the real rate of dual antiplatelet therapy (DAT, acetylsalicylic acid + clopidogrel) use in patients having appropriate indications according to current clinical guidelines and to study the possibility of prescription rate improvement by ...
S. Yu. Martsevich, V. P. Voronina, M. L. Ginzburg, N. P. Kutishenko, Yu. N. Polyanskaya, T. G. Kheliya, A. M. Malysheva, S. N. Tolpygina, V. S. Kutuzova, E. A. Gofman, A. D. Deev   +10 more
doaj   +1 more source

Analysis of the structure of consumption of antiplatelet drugs in the Russian pharmaceutical market: 2014-2016

Качественная клиническая практика, 2018
This article analyzes the volume of the Russian pharmaceutical market of antiplatelet drugs in the period 2014-2016. 80% of patients take clopidogrel generics, giving preference to Zilt®.
S. K. Zyryanov, E. V. Dumchenko
doaj  

EFFECTS OF ACETYLSALICYLIC ACID AND CLOPIDOGREL ON MORPHOFUNCTIONAL STATUS OF ERYTHROCYTES IN PATIENTS WITH ACUTE CORONARY SYNDROME

Рациональная фармакотерапия в кардиологии, 2016
Aim. In patients with acute coronary syndrome (ACS) to study an aggregation activity and morphology of erythrocytes and to assess their changes during therapy with acetylsalicylic acid, clopidogrel and combined antiplatelet therapy (acetylsalicylic acid ...
A. L. Alyavi, R. A. Rakhimov, B. A. Alyavi   +2 more
doaj   +1 more source

Фармакоэкономический анализ использования клопидогреля у пациентов с нестабильной стенокардией

Качественная клиническая практика, 2018
Цель: проведение фармакоэкономического исследования "затраты/эффективность" при использовании клопидогреля у пациентов с нестабильной стенокардией (НС) в РФ, основанного на данных исследования CURE. Методология: анализ "затраты-эффективность". Результаты.

doaj  

Antiplatelet therapy in secondary prevention of ischemic stroke

Медицинский совет, 2015
The article is a review of literature on antiplatelet (antiagregant) therapy in the secondary prevention of ischemic stroke (IS). The latest guidelines (2014) from the American Heart Association and stroke experts are discussed.
V. A. Parfyonov, S. V. Verbitskaya
doaj   +1 more source